front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |review

In the GISSI  Prevenzione, Marchioli and colleagues demonstrated that at 3 to 4 months after commencing the 850 mgs of EPA+DHA in the daily 1.0 g capsule, there was already a significant reduction in fatal arrhythmias. So the action of the fatty acids in humans comes on quickly and is seen in clinical trials of just a few years duration.. On the other hand atherosclerosis is a slow process, which takes years to develop before the coronary or cerebral arteries are so clogged by atheroma that death occurs from thromboses. That is why the answer to the question posed in this section is, “YES”. It is only that the beneficial effects in short term clinical trials will only reveal the antiarrhythmic beneficial effects. The antiatherosclerotic benefits will only be observed over long periods of time.